BILLERICA, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), a leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced that it has priced a private placement of $300 million principal amount of convertible senior notes due 2021 (the Notes). The size of the offering was increased from the previously announced $250 million principal amount due to strong investor demand. The Notes will bear interest at an annual rate of 1.25% and will mature on September 15, 2021, unless earlier converted, purchased or redeemed. Insulet also granted the initial purchasers of the Notes an option to purchase up to an additional $45 million principal amount of Notes.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD) is an innovative medical device company dedicated to making the lives of people with diabetes easier. Through its Omnipod Insulin Management System, Insulet seeks to expand the use of insulin pump therapy among people with insulin-dependent diabetes. The Omnipod is a revolutionary and easy-to-use tubeless insulin pump that features just two parts and a fully-automated cannula insertion. Insulet's Delivery Systems business also partners with global pharmaceutical and biotechnology companies to tailor the Omnipod technology platform for the delivery of subcutaneous drugs across multiple therapeutic areas. Founded in 2000, Insulet Corporation is based in Billerica, Massachusetts.